These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 1865503

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly.
    Friedman JR, Norman DC, Yoshikawa TT.
    J Am Geriatr Soc; 1989 Feb; 37(2):145-9. PubMed ID: 2910972
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
    Welz S, Hehr T, Kollmannsberger C, Bokemeyer C, Belka C, Budach W.
    Int J Radiat Oncol Biol Phys; 2007 Dec 01; 69(5):1429-35. PubMed ID: 17692474
    [Abstract] [Full Text] [Related]

  • 25. Glomerular filtration rate measurement in cirrhotic patients with renal failure.
    Roy L, Legault L, Pomier-Layrargues G.
    Clin Nephrol; 1998 Dec 01; 50(6):342-6. PubMed ID: 9877106
    [Abstract] [Full Text] [Related]

  • 26. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R.
    Cancer Chemother Pharmacol; 1997 Dec 01; 40(4):293-308. PubMed ID: 9225947
    [Abstract] [Full Text] [Related]

  • 27. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
    Raj GV, Iasonos A, Herr H, Donat SM.
    J Clin Oncol; 2006 Jul 01; 24(19):3095-100. PubMed ID: 16809735
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors.
    Tebano MT, Carlini P, Loizzo A, Luzi M, Petrucci F, Alimonti A, Caroli S.
    Ann Ist Super Sanita; 1995 Jul 01; 31(3):351-7. PubMed ID: 8712579
    [Abstract] [Full Text] [Related]

  • 31. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R, Ciccarelli A, Ariano C, Cioppa C, Giasi A, Pucciarelli A, Cantatrione S.
    Minerva Cardioangiol; 2011 Dec 01; 59(6):543-54. PubMed ID: 21330961
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Estimation of residual glomerular filtration rate and renal Kt/Vurea from creatinine clearance in end-stage renal disease patients. The Netherlands Cooperative Study on the Adequacy of Dialysis.
    Korevaar JC, Jansen MA, Dekker FW, Boeschoten EW, Krediet RT.
    Adv Perit Dial; 1999 Dec 01; 15():132-7. PubMed ID: 10682088
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function.
    Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC.
    Clin Nephrol; 1982 Jan 01; 17(1):19-23. PubMed ID: 7035042
    [Abstract] [Full Text] [Related]

  • 39. Determinants of the renal clearance of digoxin.
    Halkin H, Sheiner LB, Peck CC, Melmon KL.
    Clin Pharmacol Ther; 1975 Apr 01; 17(4):385-94. PubMed ID: 1122680
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.